B4E10042-052D-4DC4-BC94-FF1D5D4632C0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.69645203679369
- age_years
- 35
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.852
- INTERFERON_GAMMA_RESPONSE+0.728
- ALLOGRAFT_REJECTION+0.514
- IL6_JAK_STAT3_SIGNALING+0.510
- NOTCH_SIGNALING+0.484
- MYC_TARGETS_V1+0.474
- PROTEIN_SECRETION+0.468
- UNFOLDED_PROTEIN_RESPONSE+0.452
- TGF_BETA_SIGNALING+0.393
- DNA_REPAIR+0.377
Top 10 suppressed
- KRAS_SIGNALING_DN-0.365
- PANCREAS_BETA_CELLS-0.363
- SPERMATOGENESIS-0.349
- MYOGENESIS-0.250
- ESTROGEN_RESPONSE_EARLY-0.127
- ANGIOGENESIS-0.111
- ESTROGEN_RESPONSE_LATE-0.111
- BILE_ACID_METABOLISM-0.048
- HYPOXIA-0.042
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.026
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934940 | — | — | 0.947 |
| 2 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.944 |
| 3 | SRR934946 | — | — | 0.936 |
| 4 | 9ECB653A-A04F-457C-92FC-D13424511A47 | — | — | 0.936 |
| 5 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.935 |
| 6 | 4942E435-61E6-4A43-B031-4E08F0B41186 | — | — | 0.932 |
| 7 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.931 |
| 8 | 4880B586-BA92-48B2-A233-5C245D2E31C0 | — | — | 0.927 |
| 9 | C8955D29-D8EE-4F68-AEAC-CE1B838B22BF | — | — | 0.925 |
| 10 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.852 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.728 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.514 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.484 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.474 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.468 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.452 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.393 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.377 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.375 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.357 | Idelalisib | — uncovered |
| APOPTOSIS | 0.352 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.342 | Inavolisib | — uncovered |
| COMPLEMENT | 0.336 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.327 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.306 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.293 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.291 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.289 | Idelalisib | — uncovered |